Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance
Acyl CoA binding protein (ACBP) encoded by <i>DBI</i> is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in <i>Molecular Cancer</i> that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.
Authors
- Isabel Martins (ORCID: https://orcid.org/0000-0001-6797-2558)
- Guido Kroemer (ORCID: https://orcid.org/0000-0002-9334-4405)
- Léa Montégut (ORCID: https://orcid.org/0000-0003-4778-4757)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Européen (FR)
Publication Details
- Journal
- OncoImmunology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1080/2162402x.2024.2413200
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Equipex
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Institut Universitaire de France
- Institut National Du Cancer
- Direction Générale de l’offre de Soins
- Ministère des Solidarités et de la Santé
- Université de Paris
- HORIZON EUROPE Framework Programme
- European Research Council
- Labex Immuno-Oncology